US-based pharmaceuticals company Alvogen, Inc. announced on Friday that it is recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches to the consumer level.
The recalled lot is Lot 108319 25 mcg/h with expiration date April 2027.
Alvogen is recalling the product as the patches could potentially be multi-stacked, adhered one on top of the other, in a single product pouch. There is a possibility that the application of a multi-stacked 25 mcg/h patch could result in serious, life threatening, or fatal respiratory depression. The firm has received one serious adverse event related to this recall to date.
Kindeva Drug Delivery LP, Northridge, California manufactures the transdermal system, which is distributed by Alvogen, Inc. as a private label distributor.
Roivant to announce Q3 2026 financial results
Avacta secures FDA clearance for second pre|CISION oncology programme
OncoHost receives BIG Innovation Award in Health category
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Antin to acquire clinical trial equipment provider Emsere
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
Bambusa Therapeutics reports first patient dosed in proof-of-concept COPD trial
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China
INOVIO's INO-3107 Biologics License Application accepted by US FDA
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA